These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 10924312

  • 1. Congenital and acquired long QT syndrome.
    Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM.
    Eur Heart J; 2000 Aug; 21(15):1232-7. PubMed ID: 10924312
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome.
    Van Langen IM, Birnie E, Alders M, Jongbloed RJ, Le Marec H, Wilde AA.
    J Med Genet; 2003 Feb; 40(2):141-5. PubMed ID: 12566525
    [No Abstract] [Full Text] [Related]

  • 4. Molecular cardiology. Ion channels lose the rhythm.
    Welsh MJ, Hoshi T.
    Nature; 1995 Aug 24; 376(6542):640. PubMed ID: 7651510
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
    Vincent GM.
    Annu Rev Med; 1998 Aug 24; 49():263-74. PubMed ID: 9509262
    [Abstract] [Full Text] [Related]

  • 7. [Etiological mechanism of long QT syndrome and the effects of macrolides].
    Kato T.
    Jpn J Antibiot; 2001 Feb 24; 54 Suppl A():118-22. PubMed ID: 11439888
    [No Abstract] [Full Text] [Related]

  • 8. The long QT syndromes: genetic basis and clinical implications.
    Chiang CE, Roden DM.
    J Am Coll Cardiol; 2000 Jul 24; 36(1):1-12. PubMed ID: 10898405
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S, Lacroix P.
    Curr Opin Investig Drugs; 2003 Mar 24; 4(3):303-8. PubMed ID: 12735231
    [Abstract] [Full Text] [Related]

  • 14. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating.
    Tristani-Firouzi M, Sanguinetti MC.
    J Mol Cell Cardiol; 2003 Jan 24; 35(1):27-35. PubMed ID: 12623297
    [Abstract] [Full Text] [Related]

  • 15. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel.
    Tinel N, Diochot S, Borsotto M, Lazdunski M, Barhanin J.
    EMBO J; 2000 Dec 01; 19(23):6326-30. PubMed ID: 11101505
    [Abstract] [Full Text] [Related]

  • 16. Molecular diagnosis and treatment of cardiovascular diseases.
    Duff HJ.
    Can J Cardiol; 2000 Mar 01; 16(3):304-6. PubMed ID: 10744791
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.